I'm LongbridgeAI, I can summarize articles.ProKidney rose 55.76%; Calidi Biotherapeutics rose 138.03%, with a transaction volume reaching USD 171 million; Kazia Therapeutics rose 37.46%, with a transaction volume reaching USD 8.132 million; Abbvie rose 0.62%, with a transaction volume reaching USD 6.802 million, and a market capitalization of USD 336.4 billion
U.S. Stock Market Midday Update
ProKidney rose 55.76%, with trading volume surging. Based on recent important news:
-
On July 8, ProKidney announced positive results from the REGEN-007 trial, with an eGFR slope improvement of 78% and no serious adverse events, leading to a significant increase in stock price.
-
On July 8, the company stated that the results of REGEN-007 enhanced confidence in the design of the PROACT 1 trial, further driving up the stock price.
-
On July 9, management announced participation in an important meeting, with market expectations being positive, causing the stock price to continue rising.
Stocks with High Trading Volume in the Industry
Calidi Biotherapeutics rose 138.03%, with a trading volume of $171 million. According to recent key news:
-
On July 8, Calidi Biotherapeutics published an editorial on NetworkNewsWire, increasing market attention and resulting in a significant rise in stock price.
Kazia Therapeutics rose 37.46%. Based on recent important news:
-
On July 9, Kazia Therapeutics released new research results showing significant progress of its new drug in clinical trials, driving the stock price up by 37.46%.
-
On July 8, the market expressed optimism regarding Kazia's financial report, anticipating enhanced future profitability, leading to active buying by investors.
-
On July 7, industry analysts upgraded Kazia's stock rating, believing it has potential in cancer treatment, further stimulating the stock price increase.
Stocks with High Market Capitalization in the Industry
Abbvie rose 0.62%, with a market capitalization of $336.4 billion. Based on recent important news:
-
On July 9, breakthroughs in the application of CAR-T cell therapy for autoimmune diseases may bring unexpected therapeutic effects, driving Abbvie's stock price up.
-
On July 7, analysts believed Abbvie was not on the current best investment list, although rated as a moderate buy, the impact was limited.
-
On July 6, the innovative drug industry entered a golden investment window, with institutions increasing their positions, enhancing market confidence in innovative drugs